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Diffuse Large B Cell Lymphoma (DLBCL) is a highly heterogeneous disease entity (1) .
Young patients with high-intermediate and high aa-IPI score seem to be good candidates to receive alternative treatments to standard RCHOP-21 including EPOCH-R(2), R-ACVBP+HDT-ASCT(3) and upfront autologous stem cell transplantation (4) .
Other risk factors can be used to identify patients for the use of more dose-intense regimens including bulky disease, interim PET positivity and importantly, molecular profiles(5-7).
The aim of our study was to evaluate whether high dose regimens in patients enrolled in clinical trials might modify the prognostic impact of already recognized biological markers in DLBCL (Cell of Origin (COO) classification, MYC, BCL2 and BCL6 translocations, microRNA expression, MYC and BCL2 protein overexpression).
Here we have analyzed a series of 156 patient samples. Patients were enrolled in 4 clinical trials from GELTAMO, PETHEMA and GOTEL and treated using first-line dose-dense or high-dose regimens (R-CHOP 14: 76 patient samples from 209 (36%) patients; dose-adjusted EPOCH-R: 42 patient samples from 81 patients included (52%) and MegaCHOP-R plus stem cell transplantation based on interim PET results: 38 patient samples from 71 patients enrolled (53%) (8) . All received samples in the reference center were included in the study and biological marker analysis was only hampered by tissue limitations in specific cases.
A summary of the major clinical characteristics of the patients included in this study is shown in Table 1 . The studies were approved by the Institutional Ethical Committee of all participating institutions, and national regulatory agency according to the Spanish law, and complied with the Declaration of Helsinki. A retrospective cohort of 240 cases of DLBCL treated with chemoimmunotherapy was used for comparison (9) .
Centralized review of the histopathological diagnosis was performed by two hematopathologists (SMM, MAP) according to WHO classification. (1) . All cases were classified according to the COO using the immunohistochemical algorithms by Hans, Choi and Visco-Young (10-12). Immunohistochemical expression of BCL2 and C-MYC was also scored. Interphase FISH analysis was performed using Dual color Break Apart DNA probes against BCL2, BCL6 and C-MYC. microRNA expression signatures based on RT-PCR were calculated and miRNA-based survival models(9) were applied for OS and PFS in this series of patients. ROC analysis was performed to identify the higher sensitivity and specificity cutoff value for each survival function and cases were categorized into low miRNA score and high miRNA score accordingly. Kaplan Meier Survival curves and multivariate analysis were done using SPSS v11.
OS and PFS at the median follow-up time (46 months) were 83 % (±3.3%) and 79% (±3.4%). Median survival time for OS was 97. 26 months (±3.57) and median PFS were 88.04 months (±3.42). Median age was 57 years old . No significant differences were found in OS or PFS according to the study protocol (Supplementary Figure 1) .
Advanced age (>60 years) was predictive of poor OS and PFS in the univariate analysis (p <0.05) for the pooled set of patients and the RCHOP14 cases. Poor performance status was predictive of poor PFS (p <0.05, table 1) for the pooled set of cases and poor OS and PFS in the RCHOP14 cases (p= 0.001 and p=0.01 respectively). IPI risk stratification was predictive for PFS (p < 0.05) but not OS (Table 1 and Figure 1 ).
None of the IHC algorithms for COO subclassification was predictive for OS or PFS in the whole series or after treatment protocol stratification (Table 1) . Interestingly ABC type DLBCL (according to Choi´s algorithm) prognosis was significantly improved in this series when compared with the R-CHOP 21 treated control cohort (p <0.005), while GCB type DLBCL prognosis was not altered (Figure 1 ).
MYC and BCL2 protein expression was quantified according to previously published cuttoffs (9, 13, 14) . Median MYC protein expression was 30% and 54 out of 116 (46%) evaluable cases had an expression ≥40%. Median BCL2 protein expression was 50%.
Sixty seven out of 124 (54%) evaluable cases had an expression ≥50% and 53 out of 124 cases (42%) ≥70%. Neither single MYC nor BCL2 expression had independent relationship with OS or PFS. Furthermore, no significant statistical differences were found according to concurrent expression of MYC and BCL2 protein (so-called double positive cases), irrespective of the cutoff of positivity used (data not shown).
Thirty three out of 117 (28%) cases had concurrent expression of MYC and BCL2 (>50%). Thirty one out of 117 cases (26%) had coexpression of MYC and BCL2 (>70%). An association between DP cases and high stage (III-IV) disease (p<0.05) and ABC-nonGCB molecular subgroup (χ2 <0.05 using V-Y algorithm) was found. By miRNA expression signatures were found of prognostic value for OS (p log rank = 0.05) and PFS (p log rank 0.04). Cases with low miRNA score had a 90% ± 4 % PFS probability compared to 74% ± 4 % for cases with high miRNA score ( Figure 1 ). This effect was independent of advanced age in the multivariate analysis for OS (RR for age of 2.96 and RR for miRNA score of 3.31, p =0.005) and PFS (RR for age of 3.53 and RR for miRNA score of 3.76, p <0.001). Patients under 60 years and those with a low miRNA score had a probability of OS and PFS over 85% and 90% in the median follow up time, respectively. found of prognostic value for OS (p log rank = 0.05) and PFS (p log rank 0.04). Cases with low miRNA score had a 90% ± 4 % PFS probability compared to 74% ± 4 % for cases with high miRNA score. respectively) (7, 8) . Scoring for C-MYC and BCL2 was done according to previously published cuttoffs (9) (10) (11) .
RNA extraction
For quantitative PCR of FFPE samples, RNA was extracted as previously described(12, 13) with minor modifications. In brief, three 10-μm tissue sections were deparaffinized by xylene incubation. After centrifugation and an ethanol washing and drying 5 procedure, the pellet was resuspended in the lysis buffer and incubated with proteinase K (Qiagen). RNA was purified by phenol-chloroform extraction followed by isopropanol precipitation.
Real-time PCR for relative miRNA quantification using RNA from FFPE tissue and identification of a set of miRNAs associated with outcome in DLBCL.
MiRNA expression profiling of FFPE tissues was conducted using the Applied Biosystems 384-well multiplexed real-time PCR assay with 250 ng of total RNA. RNA from each case was reversed-transcribed in triplicate using a multiplex looped primer pool with the 11 selected miRNA probes (9 previously defined miRNAs: miR221, miR222, miR331, miR451, miR93, miR491, miR28, miR151, miR148a and let7a and 
General statistical methods.
Overall survival (OS) (14) was considered as the time from diagnosis to the date of death from any cause or last contact. Progression-free survival (PFS) was calculated from the time of diagnosis to the date of progression. Cases were censored on the date the patient was last known to be alive or, for patients dying as a result of causes unrelated to lymphoma or treatment, the date of death. The Kaplan-Meier method was used to estimate OS and PFS distributions (15) .The log-rank and Breslow tests were 6 used to compare survival distributions(16). The chi-square test was used to assess differences in the proportions of individual prognostic factors between series.
Multivariate analysis was performed using SPSS statistics software v11.
miRNA based survival models.
Cox regression(17) was previously used to derive survival models based on miRNA expression (of 9 selected miRNAs) (see reference (18)) . miRNA-based survival models are summarized in the following survival functions:
For OS: was performed to identify the higher sensitivity and specificity cutoff value for each survival function. Cases were categorized into low miRNA score and high miRNA score accordingly. Kaplan Meier Survival curves were plotted for OS and PFS.
